Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTO-313 in unilateral subjective tinnitus
NCT04829214Phase 2Completed
- Sponsor
- Otonomy, Inc.
- Start
- Mar 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in tinnitus comparing OTO-313 with Placebo (2 arms). Primary endpoint: Percentage of Tinnitus Functional Index (TFI) Responders at 8 weeks. Started Mar 2021; status: completed.
02
Drugs
gacyclidine
03
Conditions
tinnitus
Beyond the preview
Go deeper on NCT04829214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04829214.